Foghorn Therapeutics/ US3441741077 /

8/12/2022 9:59:55 PM	Chg. +1.06	Volume	Bid-	Ask-	High	Low
17.95USD	+6.28%	2,948 Turnover: 52,576.72	-Bid Size: -	-Ask Size: -	18.10	16.73

GlobeNewswire 3/11 Foghorn Therapeutics to Participate at the 2022 Guggenheim Targeted Protein Degradation Day

GlobeNewswire 3/10 Foghorn Therapeutics Provides Full Year 2021 Corporate Update and 2022 Outlook

GlobeNewswire 2/28 Foghorn Therapeutics to Participate at the Cowen’s 42nd Annual Health Care Conference

GlobeNewswire 1/10 Foghorn Therapeutics Announces Chief Scientific Officer Succession

GlobeNewswire 1/7 Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Conference

GlobeNewswire 12/13/2021 Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn’s Propri...

GlobeNewswire 11/11/2021 Foghorn Therapeutics to Participate at the 2021 Jefferies London Healthcare Conference

GlobeNewswire 11/9/2021 Foghorn Therapeutics Provides Third Quarter 2021 Corporate Update

GlobeNewswire 10/19/2021 Foghorn Therapeutics Announces Presentation at Upcoming 4th Annual Targeted Protein Degradation Summ...

GlobeNewswire 9/1/2021 Foghorn Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

GlobeNewswire 8/23/2021 Foghorn Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of FHD-609

GlobeNewswire 8/10/2021 Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update

GlobeNewswire 8/3/2021 Foghorn Therapeutics to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference

GlobeNewswire 7/9/2021 Foghorn Therapeutics to Participate at the William Blair Biotech Focus Conference 2021

GlobeNewswire 6/8/2021 Foghorn Therapeutics to Host Research & Development Day Webinar on June 15th

GlobeNewswire 5/26/2021 Foghorn Therapeutics to Present in Two Upcoming Investor Conferences

GlobeNewswire 5/17/2021 Foghorn Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Program of FHD-286

GlobeNewswire 5/11/2021 Foghorn Therapeutics Provides Corporate Update

GlobeNewswire 4/28/2021 Foghorn Therapeutics Appoints Ian Smith to its Board of Directors

GlobeNewswire 3/18/2021 Foghorn Therapeutics Provides Corporate Update

GlobeNewswire 3/11/2021 UPDATE: Foghorn Therapeutics to Present Poster and Chair a Panel at the AACR Annual Meeting 2021

GlobeNewswire 3/11/2021 Foghorn Therapeutics to Present Poster and Chair a Panel and at the AACR Annual Meeting 2021

GlobeNewswire 2/22/2021 Foghorn Therapeutics to Participate in the 41st Cowen Annual Healthcare Conference

GlobeNewswire 12/4/2020 Foghorn Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire 11/12/2020 Foghorn Therapeutics Appoints Michael LaCascia as Chief Legal Officer